Interim Results of Open-Label Study of IPM’s Dapivirine Vaginal Ring Find Increased Product Use and Suggest Greater HIV Risk Reduction

dream_release_croi_2018_final.pdf

Interim data from a large open-label study of the monthly dapivirine ring have found increased product use compared to a previous Phase III study. In addition, modeling data suggest that women’s HIV-1 risk in the study, known as DREAM, was reduced by more than half.

Developed by the nonprofit International Partnership for Microbicides (IPM), the monthly ring slowly releases the antiretroviral (ARV) drug dapivirine and is currently under regulatory review. The ring is designed to provide women with a discreet and long-acting HIV prevention option.

The interim analysis results were announced on 6 March, 2018 at the annual Conference on Retroviruses and Opportunistic Infections (CROI). The results:

  • show an increase in ring use over its parent Phase III study, with more than 90 percent of women in DREAM using the ring at least some of the time
  • reveal that the overall HIV incidence rate among women in the DREAM study is 54 percent lower than would be expected without use of the dapivirine ring based on statistical modeling

“We are encouraged by these interim findings because more than 35 years into the epidemic, women still lack the range of practical options they need to protect themselves against HIV.”

Filter by